Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
26P - Incidence of T790M mutations after progression on first Line EGFR TKIS in advanced NSCLC: Real time data from a tertiary cancer institute in North India (ID 422)
12:30 - 13:00 | Presenting Author(s): U. Batra
The incidence of EGFR mutations vary according to geographic region of the world. The EGFR rates in the western world are 15% whereas the incidence of EGFR mutation in the EASTERN population is 45–55%. In India, the incidence of EGFR mutation is approx. 33%. Similarly, there is a paucity of data regarding the incidence of T790 M mutation following EGFR TKIs from the Indian subcontinent. This study was therefore undertaken to analyse the incidence of T790M mutation in the Indian population following therapy with EGFFR TKIs.
EGFR mutant NSCLC stage IV patients who received Tyrosine kinase inhibitors and progressed on TKI were analysed. T790M status was determined using the droplet digital PCR.
41 patients were selected using above selection criteria. T790M mutation was detected in 22 of 41 patients (54%). 21 of 22 patients had retained the primary EGFR mutation also. Out of these 22 patients, del19 was present in 14 patients and 8 patients had L858R mutation. Most common site of progression was pleural and plural effusion. Median duration of treatment on TKI before progression is 289.7 days, highest duration being 1290 days and lowest 45 days.
Exact incidence of T790M mutations after progression on TKI s in Asian population is not exactly known and requires large data, as incidence may be different than reported in western population.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.